Prospective comparison of [ 68 Ga]Ga-FAPI-04 PET/MRI, [ 18 F]FDG PET/CT, and contrast-enhanced MRI for predicting pathologic complete response after neoadjuvant chemotherapy in breast cancer.
Eur J Nucl Med Mol ImagingJul 23, 2026 (epub)
Yuming Luo, Xiao Zhang, Runze Li et al.
✦ AI-curated · Sources linked
In 30 seconds
This prospective single-center study evaluated the effectiveness of [68Ga]Ga-FAPI-04 PET/MRI, [18F]FDG PET/CT, and contrast-enhanced MRI in predicting pathologic complete response (pCR) after neoadjuvant chemotherapy in women with stage II-III breast cancer. The study found that post-therapy [68Ga]Ga-FAPI-04 PET showed superior performance, with an AUC of 0.89 for nodal response assessment.
Key findings
- The pCR rate was 60.00% for primary lesions and 72.73% for axillary nodes.
- [68Ga]Ga-FAPI-04 PET showed an AUC of 0.84 for primary lesions and 0.89 for nodal response.
- Post-therapy [68Ga]Ga-FAPI-04 SUVmax had sensitivity, specificity, and accuracy of 80.00% each for primary lesions.
- Stromal FAP expression positively correlated with [68Ga]Ga-FAPI-04 SUVmax.
Why it matters
Accurate assessment of treatment response in breast cancer is crucial for optimizing patient management. This study suggests that [68Ga]Ga-FAPI-04 PET may enhance response evaluation, particularly for axillary nodes, potentially leading to more tailored surgical planning.